Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Net Cash Flow (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Net Cash Flow for 4 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 163.75% to $9.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$320.8 million through Dec 2025, down 226.32% year-over-year, with the annual reading at -$320.8 million for FY2025, 226.32% down from the prior year.
  • Net Cash Flow for Q4 2025 was $9.5 million at Centessa Pharmaceuticals, up from $7.1 million in the prior quarter.
  • The five-year high for Net Cash Flow was $269.6 million in Q3 2024, with the low at -$276.5 million in Q1 2025.
  • Average Net Cash Flow over 4 years is -$33.4 million, with a median of -$40.9 million recorded in 2022.
  • The sharpest move saw Net Cash Flow skyrocketed 934.45% in 2024, then tumbled 2656.93% in 2025.
  • Over 4 years, Net Cash Flow stood at -$51.9 million in 2022, then increased by 17.25% to -$43.0 million in 2023, then soared by 65.47% to -$14.8 million in 2024, then soared by 163.75% to $9.5 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $9.5 million, $7.1 million, and -$60.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.